Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Alterity Therapeutics
Company

Alterity Therapeutics

Tracked across 1 events · 7 articles · First seen Jul 07, 2026 · Last active Jul 07, 2026

Sentiment
40
Attention
3
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
3 40
Regulatory
Alterity receives FDA Phase 3 pathway for ATH434
Impact: Alterity received FDA confirmation of a streamlined Phase 3 pathway for its lead drug ATH434, reducing development risk and bringing it closer to potential approval.
Jul 07, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Alterity Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.